FUJIFILM Biosciences and NextCell launch platform for stromal cell research
New research‑use platform combines MSC cells and culture media to support immunology and regenerative medicine workflows
8 May 2026Product news
FUJIFILM Biosciences and NextCell Pharma AB, a clinical-stage cell therapy company, have launched a new mesenchymal stromal cell (MSC) research platform. The platform combines FUJIFILM Biosciences’ PRIME-XV MSC Expansion XSFM medium with NextCell Pharma AB’s first commercial product, NextCell-Cord RUO, a research-use-only (RUO) MSC product derived from umbilical cord tissue, to support researchers in immunology, regenerative medicine, and cell therapy development.
New MSC research platform to address key scientific challenges
The collaboration between FUJIFILM Biosciences and NextCell Pharma AB is designed to help researchers overcome persistent challenges in MSC research, including heterogeneity of MSCs, immunocompatibility issues, and inefficient manufacturing processes.
By pairing NextCell-Cord RUO stromal cells with PRIME-XV MSC Expansion XSFM medium, the companies aim to provide a high-quality, standardized, and accessible solution for laboratories worldwide.
NextCell-Cord RUO offers researchers a more consistent, efficient, and readily available source of umbilical cord-derived MSCs. When combined with FUJIFILM Biosciences’ PRIME-XV MSC Expansion XSFM medium, recombinant growth factors, and reagents, the platform supports robust MSC expansion and streamlined workflows for research and development.
“We’ve worked with FUJIFILM Biosciences to ensure that this product meets the needs of researchers and drug developers who value consistency, scalability, and translational relevance,” said Dr. Lindsay Davies, chief scientific officer at NextCell Pharma AB. “NextCell-Cord RUO reflects not only our clinical manufacturing expertise, but also a commitment to delivering high-quality, standardized MSC products that are scientifically robust and immediately usable in research and development workflows.”
Brandon Pence, president and chief operations officer at FUJIFILM Biosciences, added, “FUJIFILM Biosciences is committed to paving a better way forward with life science products, services, and solutions that serve the evolving needs of our academia, biotech, and pharmaceutical partners worldwide. Our strategic alliance with NextCell Pharma further strengthens our commitment to enabling our customers to achieve more with products and solutions they need every day to help create a healthier world for all.”
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>
Frequently asked questions
What is the new mesenchymal stromal cell (MSC) research platform launched by FUJIFILM Biosciences and NextCell Pharma AB, and which life science applications does it support?
The new MSC research platform is a global commercial offering that combines FUJIFILM Biosciences’ PRIME-XV MSC Expansion XSFM medium with NextCell Pharma AB’s NextCell-Cord RUO, a research-use-only MSC product derived from umbilical cord tissue. This integrated platform is designed to support researchers working in immunology, regenerative medicine, and cell therapy development by providing a high-quality, standardized, and accessible solution for MSC research.
How does the FUJIFILM Biosciences and NextCell Pharma AB collaboration address key challenges in MSC research, such as heterogeneity and manufacturing efficiency?
The collaboration between FUJIFILM Biosciences and NextCell Pharma AB aims to tackle persistent MSC research challenges, including MSC heterogeneity, immunocompatibility issues, and inefficient manufacturing processes. By pairing NextCell-Cord RUO stromal cells with PRIME-XV MSC Expansion XSFM medium, recombinant growth factors, and reagents, the platform offers a more consistent, efficient, and readily available source of umbilical cord-derived MSCs. This combination supports robust MSC expansion, streamlined workflows, and standardized, scientifically robust products for research and development.
Where is NextCell-Cord RUO available globally, and which types of organizations are the primary users of this MSC platform?
NextCell-Cord RUO is distributed through FUJIFILM Biosciences’ global commercial network and can be accessed across all major international markets. The combined platform is intended for researchers in academia, biotechnology, and pharmaceutical organizations that focus on immunology, regenerative medicine, and cell therapy development.
It is supplied as cryopreserved, research-use-only MSCs and can be purchased either as a standalone product or bundled with PRIME-XV MSC Expansion XSFM medium, recombinant growth factors, and reagents.